Fig. 2From: The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s diseaseAmyloid and tau biomarkers can be used to confirm AD pathology, and biomarkers of synaptic damage and loss will be useful for predicting cognitive declineBack to article page